Are statins beneficial for viral pneumonia?

Angela R. Boyd, Eric M. Mortensen

Source: Eur Respir J 2013; 41: 1010-1011
Journal Issue: May
Disease area: Respiratory infections

Full text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Angela R. Boyd, Eric M. Mortensen. Are statins beneficial for viral pneumonia?. Eur Respir J 2013; 41: 1010-1011

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Are corticosteroids useful in community-acquired pneumonia?
Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia
Year: 2006


The use of antiviral drug Ribavirin in cases of viral-bacterial community acquired pneumonia
Source: International Congress 2018 – Pleural diseases and pneumonia: what's new ?
Year: 2018

Interactions between bacterial and viral infections during COPD exacerbations: implications for prevention strategies
Source: International Congress 2019 – Scientific Year in review
Year: 2019


Risk of adverse effects of antitubercular drugs in patients with pulmonary tuberculosis and low active viral hepatitis C and other digestive tract diseases
Source: Annual Congress 2008 - Tuberculosis in immigrants, disadvantaged populations, elderly, HIV-seropositives and in other risk groups
Year: 2008


The risk of community-acquired pneumonia and the use of statins, ACE inhibitors and gastric acid suppressants
Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis
Year: 2008


What is pneumonia?
Source: Breathe, 17 (3) 210087; 10.1183/20734735.0087-2021
Year: 2021



Potential synergism of drugs with anti-viral and pulmonary oedema clearance activity may be advantageous for influenza patients
Source: Annual Congress 2011 - Insight into mechanisms of respiratory infections
Year: 2011

Risk factors and outcomes of severe influenza pneumonia with bacterial co-infection in critically ill patients
Source: International Congress 2017 – Sepsis, infections, ARDS and beyond
Year: 2017


Antibiotics in RSV bronchiolitis: still no evidence of effect
Source: Eur Respir J 2007; 29: 1285
Year: 2007


Antibiotics in hospitalised infants with acute bronchiolitis. Is there enough evidence for prescribing?
Source: Eur Respir J 2005; 26: Suppl. 49, 28s
Year: 2005

Is COPD pharmacotherapy associated with increased incidence of community-acquired pneumonia?
Source: Annual Congress 2008 - Community-acquired pneumonia and COPD: what do we know?
Year: 2008


Antibiotics in acute exacerbations: what do we need?
Source: Annual Congress 2005 - Infection and acute exacerbation of COPD: what do we know?
Year: 2005

Influenza viruses as etiologic agents of the acute respiratory infections in infancy and early childhood - is their role underestimated?
Source: Eur Respir J 2002; 20: Suppl. 38, 176s
Year: 2002

How often can we use short course therapy in patients with hospital-acquired pneumonia?
Source: Eur Respir J 2007; 30: Suppl. 51, 408s
Year: 2007

Update on therapeutic strategies in community-acquired pneumonia   
Source: International Congress 2017 – PG17 Infectious disease challenges in community-acquired pneumonia and tuberculosis: improving your clinical practice
Year: 2017


Statin therapy and reduced risk of pneumonia in elderly patients with diabetes
Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia
Year: 2006